The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced (nonresectable) and metastatic biliary tumors: A randomized double-blinded placebo-controlled phase II trial.
 
Anne Demols
Consulting or Advisory Role - Bayer Health; Helsinn Healthcare; Ipsen
Research Funding - Bayer Health
 
Ivan Borbath
Consulting or Advisory Role - Novartis (Inst)
Research Funding - Celgene (Inst); Ipsen (Inst); Novartis (Inst)
 
Marc Van Den Eynde
No Relationships to Disclose
 
Ghislain Houbiers
No Relationships to Disclose
 
Marc Peeters
No Relationships to Disclose
 
Raphael Maréchal
No Relationships to Disclose
 
Thierry Delaunoit
No Relationships to Disclose
 
Jean Charles. Goeminne
No Relationships to Disclose
 
Stéphanie Laurent
No Relationships to Disclose
 
Stephane Holbrechts
No Relationships to Disclose
 
Marianne Paesmans
No Relationships to Disclose
 
Jean L. Van Laethem
No Relationships to Disclose